Company intelligence / Profile preview
Bio-Cancer Treatment International Limited
Sha Tin, New Territories, Hong Konghkstp.org ↗
- Ownership
- Private
- Employees
- ~13
- Development stage
- Phase 2
01
Overview
BCT-100 is in phase I clinical trial in the US for arginine-auxotrophic solid cancers and phase II clinical trials in the UK for acute myeloid leukemia in combination with low dose cytarabine in elderly patients and in sarcomas, AML and neuroblastoma in pediatric patients.
- Therapeutic areas
- OncologyImmunology
- Modalities
- BiologicsPegylated recombinant human arginase 1 (pegArg1)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
I-Mab Biopharma
Beyond the preview
Go deeper on Bio-Cancer Treatment International Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bio-Cancer Treatment International Limited.